Ritodrine treatment for uterine hyperactivity during the active phase of labor

Area of Science:

• Obstetrics and Gynecology
• Pharmacology

Background:

• Uterine hyperactivity, including tachysystole and hypertonus, can complicate the active phase of labor.
• Fetal heart rate distress is a significant concern associated with uterine hypercontractility.

Purpose of the Study:

• To evaluate the efficacy of intravenous ritodrine in treating uterine hyperactivity during labor.
• To assess the impact of ritodrine on uterine dysfunction and fetal well-being.

Main Methods:

• Forty patients with uterine hyperactivity received intravenous ritodrine, with dosages titrated from 50 to 300 micrograms/min.
• Treatment response was monitored, and labor duration and delivery outcomes were analyzed.

Main Results:

• Eighty-five percent of patients (34/40) showed resolution of uterine dysfunction within 20 minutes.
• All instances of concomitant fetal heart rate distress (21/40) resolved with ritodrine treatment.
• Labor duration was not prolonged and was significantly correlated with parity and cervical dilation at treatment initiation.

Conclusions:

• Intravenous ritodrine is an effective treatment for uterine hypercontractility dysfunction.
• Ritodrine rapidly resolves uterine dysfunction and associated fetal heart rate distress.
• The treatment does not appear to prolong labor, suggesting its utility in managing labor complications.